Navigation Links
Drug Safety Firm BioSoteria Announces Exponential Growth in 2009

BioSoteria announced today that revenues grew 67% in 2009 compared to 2008. The strong growth came from an increase in new client contracts, expanded drug safety services to existing clients, and the launch of eLadder™ Safety, a comprehensive pharmacovigilance eLearning curriculum.

(PRWEB) January 28, 2010 -- BioSoteria, Inc., a privately held drug safety services and training company, announced today that revenues grew 67% in 2009 compared to 2008. The strong growth came from an increase in new client contracts, expanded services to existing clients, and the launch of eLadder™ Safety, a first-in-class comprehensive pharmacovigilance eLearning curriculum.

In 2009, BioSoteria provided consulting and safety operational services to more than 40 biotechnology and pharmaceutical companies across the US and Canada. The company’s substantial increase in revenues in 2009 was realized as clients increasingly engaged BioSoteria for strategic consulting and services in areas such as risk evaluation and mitigation strategies (REMS) and safety signal detection and analysis. Professional staff grew by 19% to support the demand for BioSoteria’s drug safety services and training offerings.

Also contributing to the increase in corporate growth was the launch of BioSoteria’s eLadder™ Safety pharmacovigilance training curriculum. The first three eLearning courses of the curriculum released in 2009 were enthusiastically received by drug safety professionals, those aspiring to enter the field of drug safety, and by biopharmaceutical companies and contract research organizations (CROs) that wish to train their safety personnel. The BioSoteria website was upgraded to include an eCommerce engine that allows individuals and small companies to purchase access to eLadder™ Safety courses online. Enterprise license options for corporate/institutional buyers were also introduced.

“I am very pleased with our leadership position in drug safety and continued growth of our company in 2009,” said Sally Van Doren, PharmD, President, CEO and Founder of BioSoteria. “In just three years, BioSoteria has grown from a small consulting firm providing services to primarily West Coast clients to a well recognized, full-service pharmacovigilance service and training provider across North America with a dedicated team of nearly 50 drug safety professionals, educational and training staff and operational support. We look forward to continuing our high quality services and extending our offerings in 2010 through business expansion and strategic partnerships.”

Highlights of 2009
-- Safety consulting and operational services were provided to more than 40 biotechnology, pharmaceutical, and over-the counter (OTC) companies, including:

  • Case intake, data entry, narratives, coding, reporting to regulatory authorities, periodic safety reporting, company core data sheet (CCDS) development and maintenance, and labeling updates
  • Patient narratives, integrated summary of safety (ISS) and other medical writing support for NDAs, BLAs, and MAAs
  • Hosted safety database solutions
  • Risk management/REMS planning, document writing, and implementation
  • Safety signal detection and analysis using client, FDA AERS, and other health databases
  • Pharmacovigilance department audits and US/EU inspection readiness
  • Product litigation consulting and support
  • Support to clients with complete response letters and programs placed on clinical hold

-- eLadder™ Safety, the first comprehensive drug safety training curriculum delivered in a true multimedia eLearning environment, was launched, with three core competency courses for drug safety professionals:

-- The BioSoteria leadership team expanded with the addition of James Buchanan, PharmD, as Senior Vice President of Pharmacovigilance and Risk Management. Dr. Buchanan has more than 20 years of industry drug safety, clinical development, and medical information services experience, and he has served as Chief Safety Officer at two past companies prior to joining BioSoteria.

-- BioSoteria moved its corporate headquarters to Emeryville CA, central to many biotechnology and pharmaceutical companies in the San Francisco Bay Area, to accommodate the current and future growth in its staff and drug safety services.

-- DSI: Drug Safety Intelligence, BioSoteria’s weekly drug safety e-newsletter, grew to nearly 1100 subscribers.

-- BioSoteria’s 3rd Annual Pacific Drug Safety Summit ( PDSS09) had the highest attendance, sponsorship and satisfaction rankings to date, making it one of the most well attended pharmacovigilance conferences in the US of the year.

-- Several of the BioSoteria senior management team accepted faculty and instructor appointments and lectured throughout the year at Universities, Schools of Pharmacy, as well as industry conferences, on drug development and drug safety.

About BioSoteria, Inc.
BioSoteria provides innovative drug safety services and educational programs to the biopharmaceutical industry. The company offers a wide range of pharmacovigilance services throughout the product lifecycle, including premarketing clinical safety surveillance, postmarketing pharmacovigilance, and risk management programs. For more information about BioSoteria, please visit the company’s website at, email, or call 1-866-660-5553.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. RFID tags to boost transit worker safety
2. FDA researchers identify new MRI safety risk for patients with pacemakers
3. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
4. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
5. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
6. BioSoteria CEO to Present at Drug Safety Conference
7. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
8. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
9. BioSoteria Drug Safety Newsletter Reaches Milestone
10. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production
11. Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, ... (ECNR) in Vienna, Austria to ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ... of its Internet-delivered NovaVision Therapy Suite at the 3rd ...
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):